There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (EW – Research Report), Humana (HUM – Research Report) and Thermo Fisher (TMO – Research Report) with bullish sentiments.
Edwards Lifesciences (EW)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Edwards Lifesciences on January 31 and set a price target of $95.00. The company’s shares closed last Friday at $82.12.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $86.56 average price target, implying a 3.6% upside from current levels. In a report issued on February 1, Evercore ISI also maintained a Buy rating on the stock with a $84.00 price target.
See the top stocks recommended by analysts >>
Humana (HUM)
RBC Capital analyst Ben Hendrix maintained a Buy rating on Humana on February 1 and set a price target of $637.00. The company’s shares closed last Friday at $476.57.
According to TipRanks.com, Hendrix is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humana with a $619.86 average price target, which is a 26.1% upside from current levels. In a report issued on January 17, Wells Fargo also maintained a Buy rating on the stock with a $610.00 price target.
Thermo Fisher (TMO)
In a report issued on February 2, Conor McNamara from RBC Capital maintained a Buy rating on Thermo Fisher, with a price target of $655.00. The company’s shares closed last Friday at $587.76.
According to TipRanks.com, McNamara is a 3-star analyst with an average return of
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $651.00, an 11.4% upside from current levels. In a report issued on January 20, Bank of America Securities also maintained a Buy rating on the stock with a $650.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EW:
- Early notable gainers among liquid option names on February 1st
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50
